Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...
The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1,” published in the March 2025 issue of ...
Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...
Elevation Oncology (NASDAQ:ELEV – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by research analysts at ...
Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and ...
As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...
Manuscript Summary Submission Deadline 30 May 2025 | Manuscript Submission Deadline 29 June 2025 | Manuscript Extension Submission Deadline 30 July 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback